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Research and development in stroke services
Is taking off in the United Kingdom
Stroke affects people of the same age and in thesame numbers as coronary heart disease1;thrombolytic therapy is highly effective for
selected patients in the first three hours2; and both
treatment in stroke units3 and immediate brain
imaging4 are cost effective. Yet patients and the public
have low expectations of outcomes after stroke.
Moreover, as the National Audit Office (NAO)
reports, stroke is not afforded the same priority by the
NHS as other serious diseases.5 The NAO argues that
the NHS lacks sufficient emergency responses to stroke
and effective acute care, provides too few services for
rehabilitation and support after discharge from hospital
for both patients and carers, and does too little to
prevent stroke. The last important lever for improving
services for stroke was the national service framework
for older people (2001),6 which did seed services in most
NHS hospitals, but there is still much to do.
This week the UK government’s Public Accounts
Committee will hear the findings of the NAO report
on stroke and the government’s response to it. Along
with other recent developments, this could provide a
real opportunity to improve services for patients with
stroke.
One essential development is to foster a culture of
research on stroke. The UK Stroke Research Network
(www.uksrn.ac.uk) is starting to provide an infrastruc-
ture for research on this disease, supported by £20m
over five years from the Department of Health. By
establishing local research groups in England, the net-
work will facilitate clinical research in prevention,
primary care, acute care, and rehabilitation for stroke.
It will also perform a detailed baseline analysis of the
current NHS infrastructure for research in stroke and
will identify local barriers to such studies.
General practitioners now maintain registers of
patients with stroke and follow up these patients regu-
larly, offering new opportunities for studies in primary
care. And, despite short term research contracts and
few formal research posts, the number of academics
working in stroke rehabilitation is increasing.
Patients, carers, and the public have so far
participated in only a limited way in developing
services for and research on stroke in the UK.7 The
public needs to know more about stroke. The Stroke
Association’s recently launched campaign, “Stroke is a
Medical Emergency,” is raising public awareness of
the warning signs of stroke.8 Almost all patients
with stroke are treated in the NHS, where acute serv-
ices are increasingly well integrated with rehabilitation
units.
The capacity of services for stroke remains a barrier
to both high quality care and research. Many NHS
acute stroke units are keen to introduce thrombolysis
and to participate in randomised controlled trials,
despite difficulties in assessing patients and using
imaging urgently. Although the proportion of patients
treated on a stroke unit has increased (from 36% in
2001 to 47% in 2004), only 41% of patients in 2004
spent more than half of their time as inpatients in such
units.9 Rapid access to investigations within the NHS,
particularly brain imaging, is another challenge. Fewer
than 20% of stroke units have access to computed tom-
ography within three hours of admission, and most
patients wait more than two days.9 There is a national
shortage of the allied health professionals required to
staff multidisciplinary teams for stroke, and few such
staff actively participate in research because there is no
career framework for them in research.
Complicated regulation of research has hampered
clinical research on stroke.10 The recently launched
research and development strategy for the NHS, Best
Research for Best Health,11 should strengthen and
streamline systems for managing and governing
research, however, and should reduce substantially the
burden and delays that clinical researchers face.
Stroke care costs the NHS £2.8bn a year in direct
care costs (more than the direct costs of coronary heart
disease) and costs the nation £1.8bn in lost productiv-
ity and disability.1 Patients, carers, professionals, and
researchers must evaluate critically any actions in
response to the NAO report. This is a time of real
opportunity to spend this money more effectively.
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